Cochlear Ltd
ASX:COH
Cochlear Ltd
Total Equity
Cochlear Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cochlear Ltd
ASX:COH
|
Total Equity
AU$1.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
|
Somnomed Ltd
ASX:SOM
|
Total Equity
AU$47.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
19%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Total Equity
AU$42.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Total Equity
AU$11.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
76%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Total Equity
AU$44.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Total Equity
AU$15.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
Glance View
Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.
See Also
What is Cochlear Ltd's Total Equity?
Total Equity
1.9B
AUD
Based on the financial report for Dec 31, 2024, Cochlear Ltd's Total Equity amounts to 1.9B AUD.
What is Cochlear Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
19%
Over the last year, the Total Equity growth was 5%. The average annual Total Equity growth rates for Cochlear Ltd have been 3% over the past three years , 18% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet